Rapid efficacy of efgartigimod for generalized myasthenia gravis patients in acute exacerbations/worsening: multicenter real-world retrospective study - PubMed
6 days ago
- #Myasthenia Gravis
- #Efgartigimod
- #Acute Exacerbation
- Efgartigimod shows rapid efficacy for generalized myasthenia gravis (gMG) patients in acute exacerbations/worsening.
- The study involved 61 gMG patients who received weekly efgartigimod infusions for 4 weeks.
- Clinical meaningful improvement was observed in 81.9% of patients after the first dose (W1), increasing to 98.1% by W4.
- Significant reductions in MG-ADL and QMG scores were noted: 80.86% and 55.81% at W4, and 70.78% and 47.76% at W7.
- Patients with myasthenic crisis (MC) red flags, such as pulmonary infection (26.2%), achieved comparable outcomes.
- Greater improvements were seen in patients with thymoma history, severe MGFA classification, prior MC, or MC red flags.
- No treatment-related allergic reactions, infections, or serious adverse events were reported.
- The study supports efgartigimod as a valuable therapeutic option for high-risk gMG patients.